Sri Lanka, Nov. 26 -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that updated results from the ongoing pivotal
Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES)trial of its dengue vaccine candidate (TAK-003) were presented at the American Society of Tropical Medicine and Hygiene (ASTMH) 68 th Annual Meeting. The data presented include an update on overall vaccine efficacy (VE) and a formal assessment of secondary efficacy endpoints by serotype, baseline serostatus and disease severity (18 months after the second dose, which was administered three months after the first dose). The TIDES trial met all secondary endpoints for which there were a sufficient number of cases. Overall vaccine efficacy and...